Journal of Leukemia
Open Access

Department of Hematology, Union Hospital, No. 29 Xinquan Road, Fuzhou, Fujian 350001, People's Republic of China

Biography

Shimuye Kalayu Yirga has done his PhD student in the School of Life Sciences, Fujian Agriculture and Forestry University in China. Since 2013, he has been working as a Lecturer at Woldia University in Ethiopia.

Publications

• Review Article   
  Development of Therapeutic Antibody Technology And Recent Perspectives For Leukemia-Lymphoma Treatment
  Author(s): Shimuye Kalayu Yirga*, Minhui Lin, Zhongyang Huang and Jianda Hu
  
  Advancement of monoclonal antibodies (Mabs) to be accepted as a therapy has long history. This article describes the dramatic developmental trend of therapeutic antibody technology and their significant role for treatment of leukemia-lymphoma at the current time. The therapeutic Mab technology development from murine (mouse origin) to fully human resulted in low immunogenicity and high quality Mabs. Chemotherapy is standard care for leukemialymphoma treatments. However, it is associated with high toxicities (side effects), painful and relatively ineffective against certain leukemia-lymphoma subtypes. The remarkable contribution of Von Behring, Paul Ehrlich and the discovery of hybridoma technology marked the beginning of antibodies for therapeutic applications. Rituximab is the first Mab approved by Food and Drug Administration against B-cell malignancies. Today, a number of effective.. View More»
  DOI: 10.35248/2329-6917.19.7.259

  Abstract HTML PDF